Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):158-65

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2021 May;180(5):158-65

DOI: 10.23736/S0393-3660.19.04196-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

The role of colchicine in preventing contrast-induced acute kidney injury in patients undergoing elective percutaneous coronary intervention

Veysel OKTAY , Ilknur C. CIRALI, Mert SARILAR, Khayel MIRZAYEV, Urfan JAFAROV, Okay ABACI

Department of Cardiology, Institute of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey



BACKGROUND: Contrast induced acute kidney injury (CI-AKI) is a serious complication of percutaneous coronary interventions (PCI) and is associated with increased morbidity and mortality. The aim of this study was to investigate the preventive role of colchicine on CI-AKI in patients undergoing elective PCI considering to its anti-inflammatory and renoprotective effects.
METHODS: This study was designed as a single-centered, randomized, and open-label study including 280 patients undergoing elective PCI with an estimated glomerular filtration rate (eGFR) of >45 mL/min/1.73 m2. One-hundred-forty patients were randomized to the colchicine treatment group (mean age, 60±9 years), whereas 140 patients were randomized to the control group (mean age, 61±7 years). CI-AKI was defined as either a 50% relative increase in serum creatinine levels from the baseline or a 0.3 mg/dL increase in the absolute value that measured 48 h after PCI. Colchicine treatment was started 24 hours before the PCI and continued 48 hours after PCI. Logistic regression analysis was performed to identify the independent predictors of CI-AKI.
RESULTS: CI-AKI occurred in 6 of the 140 patients (4%) in the colchicine group and in 13 of the 140 patients (9%) in the control group (odds ratio [OR]: 0.42; 95% confidence interval [CI]: 0.20 to 0.82; P=0.02). In patients under colchicine treatment, the rate of eGFR reduction after PCI was significantly lower than in that in those not under colchicine treatment (69±13 vs. 66±15, P=0.227; 72±11 vs. 63±13 P<0.001). In logistic regression analysis, age (OR=1.3, 95% CI: 1.1-1.6, P=0.005), diabetes mellitus (OR=2.24 95% CI: 1.17-3.31, P<0.001) and colchicine treatment (OR=0.84, 95% CI: 0.72-0.98, P=0.020) were independent predictors of CI-AKI.
CONCLUSIONS: Prophylactic oral administration of colchicine may protect against CI-AKI in patients undergoing elective PCI with mildly or moderately decreased eGFR values.


KEY WORDS: Acute kidney injury; Colchicine; Percutaneous coronary intervention

top of page